The impact of  breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden by unknown
RESEARCH ARTICLE Open Access
The impact of in situ breast cancer and
family history on risk of subsequent breast
cancer events and mortality - a population-
based study from Sweden
Helena Sackey1,6*, Miao Hui2, Kamila Czene3, Helena Verkooijen4, Gustaf Edgren3,7, Jan Frisell1,6 and
Mikael Hartman1,2,5
Abstract
Background: The clinical behavior of in situ breast cancer is incompletely understood and several factors have
been associated with invasive recurrence. The purpose of this study was to evaluate long-term risk of subsequent
breast cancer and mortality among women diagnosed with in situ breast cancer, in relation to family history
Methods: Using the population-based Swedish Multi-Generation and Cancer Registers we identified 8111 women
diagnosed with in situ breast cancer between 1980 and 2004. We used standardized incidence ratios (SIRs) to
measure the relative risk of subsequent invasive or contralateral in situ breast cancer and standardized mortality
ratios (SMRs) for relative risks of death.
Results: Among women diagnosed with in situ breast cancer, the cumulative 10-year and 20-year risk for
subsequent contralateral or ipsilateral invasive cancer was approximately 10 % and 18 %, respectively. The risk of
subsequent invasive breast cancer was increased more than 4-fold (SIR 4.6 (95 % CI 4.2 − 4.9)) among women with
in situ breast cancer as compared to women in the general population and the risk of contralateral in situ breast
cancer was increased almost 16-fold (SIR 16.0 (95 % CI 13.2–19.1)). Having a family history of breast cancer
increased the risk of contralateral invasive breast cancer by almost 50 % (incidence rate ratio 1.5 (95 % CI 1.0–2.0)).
Women under forty years old at diagnosis, without family history, had a 7-fold increased risk, and those with a
family history had a 14-fold increased risk for subsequent invasive breast cancer with SIRs of 7.2 (95 % CI 4.8–10.5)
and 14.3 (95 % CI 7.4–25.0), respectively. The overall risk of death in women with in situ breast cancer was
significantly increased by 30 % compared to the general population but was highly dependent on the occurrence
of a second invasive cancer event (SMR 1.3 (95 % CI 1.2–1.4)).
Conclusions: Among women with in situ breast cancer, a positive family history increases the risk of contralateral
invasive breast cancer by almost 50 %. The risk of subsequent invasive breast cancer and mortality is substantially
higher in younger women, which should be taken into account when planning their treatment and follow up.
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Background
Women with in situ breast cancer have an increased risk of
developing in situ or invasive breast cancer in the ipsilateral
or contralateral breast [1–12]. Moreover women with in
situ breast cancer, even after treatment, are at increased risk
of subsequent invasive breast cancer compared to women
in the general population [1, 3–9, 13–16]. The clinical be-
havior of in situ breast cancer is incompletely understood
but it is likely that it represents a mixed population of
indolent and more aggressive tumors. Several factors have
been associated with invasive recurrences, including patient
characteristics [4, 5, 8], tumor characteristics [4, 5, 17] and
treatment [4, 18, 19]. The influence of a positive family
history on subsequent breast cancer is less well-studied
[20–22].
The risk of death from breast cancer in women
diagnosed with in situ breast cancer is considered to be at
most only marginally increased, but remains less well-
characterized and, with few exceptions, studies are often
limited by short follow up and non-population-based de-
signs [14, 23]. In this study we evaluated the long-term
risk of second breast cancer and death among women
diagnosed with in situ breast cancer, in relation to family
history.
Methods
We combined data from the Multi-Generation Register
(including more than 11 million individuals, from around
3 million families) with the Swedish Cancer Register, the
Cause of Death Register and the Total Population Register
for data on emigration. These registers were merged using
the unique national registration number that all Swedish
citizens receive at birth or immigration. Linkages provide
complete follow up with of cancers, vital status, date and
cause of death, and dates of immigration and emigration.
It also provides links between children and parents
through their respective national registration numbers.
The Swedish Cancer Register is a nationwide,
population-based register that contains information on
virtually all diagnosed cancers in Sweden since 1958 and
is considered almost complete for invasive cancer [24–
26] and of very high reliability for in situ breast cancer
from 1980 onwards [26]. The tumor site is classified ac-
cording to international classification of disease (ICD).
Any invasive cancer following in situ breast cancer is
reported as a new event, as are new in situ breast
cancers in the contralateral breast. Local relapses are not
recorded, neither are new ipsilateral in situ events. The
register does not distinguish ductal from lobular in situ
breast cancer before 1990 and contains no information
on tumor stage or treatment. Ipsilateral in situ breast
cancer was excluded due to the increased probability of
being underreported in women with previous in situ
breast cancer.
Thus, we defined subsequent breast events as ipsilateral
or contralateral invasive or a contralateral in situ breast
cancer. Women with any previous invasive or in situ
breast cancer were excluded, as were women with invasive
breast cancer diagnosed concurrently with the first in situ
breast cancer. Family history of breast cancer was defined
as having at least one first-degree relative diagnosed with
invasive breast cancer at any point in time. For all women,
we collected information on family history of breast
cancer and all second primary cancers including type of
cancer, laterality and date of diagnosis. Because of incom-
plete information on laterality and in situ breast cancer
registration prior to 1980 [26], we restricted our cohort to
women with a first in situ breast cancer diagnosed in the
period 1980 to 2004. Our final study population consisted
of 8111 women in the Swedish Multi-Generation Register,
diagnosed with first in situ breast cancer between 1
January 1980 and 1 January 2005.
Statistical analyses
Risk of subsequent breast events following in situ
breast cancer
To estimate the risk of a subsequent breast event
(ipsilateral or contralateral invasive or contralateral in
situ breast cancer), all women were followed from the
date of their first in situ breast cancer diagnosis and
continued until a subsequent breast cancer, emigration,
death, or end of follow up, whichever came first. We
estimated standardized incidence ratios (SIRs), i.e., the
ratio of the observed to the expected number of breast
cancers (ipsilateral or contralateral invasive or contralat-
eral in situ breast cancer), as a measure of relative risk.
The expected number of subsequent breast cancer
events was calculated as the product of the person-years
accumulated by women with in situ breast cancer by the
age-specific and calendar-period-specific incidence of
unilateral in situ/invasive breast cancer in the general
population in the Swedish Multi-Generation Register.
For all estimates for the contralateral breast, the
background rate of in situ and invasive breast cancer was
divided by two, as only one breast was “at risk”. Thus, SIRs
compare sex-adjusted, age-adjusted and calendar-period-
adjusted risk of subsequent events (ipsilateral or contralat-
eral invasive or contralateral in situ breast cancer) among
patients with in situ breast cancer to the risk among the
general population, and were stratified by family history of
breast cancer. SIRs of subsequent invasive breast cancer
were calculated for the calendar period of the first diagno-
sis, age and time since first diagnosis. Poisson trend tests
for monotonic trend of SIRs across calendar period, age
and time since first diagnosis was performed [27]. We
used Poisson regression modeling among women with a
first in situ breast cancer to estimate the independent
effects of age, year and time since diagnosis and effect of
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family history on the risk of ipsilateral or contralateral
invasive or contralateral in situ breast cancer.
As background rates of breast cancer vary considerably
by age we also estimated excess additive risks (EARs), as
the difference of observed numbers of subsequent invasive
breast cancers and the expected numbers in the general
population in the Swedish Multi-Generation register, as a
measure of absolute risk for subsequent invasive cancer.
EARs were estimated using a univariate Poisson model with
an identity link function and the expected number of cases
as the offset. The likelihood ratio test was used to calculate
95 % confidence intervals (CIs). The cumulative incidence
was estimated using the life-table (actuarial) method.
Risk of death following in situ breast cancer
The standardized mortality ratio (SMR), i.e., the ratio of
the observed to the expected number of deaths,
standardized by age and calendar period, was used as a
measure of relative mortality. The expected number of
deaths was calculated from the general population in the
Swedish Multi-Generation register. SMRs were also
stratified by family history, age at first in situ breast
cancer diagnosis and type of subsequent breast event.
For overall SMRs, subjects were followed from the date
of the first in situ breast cancer diagnosis until the date
of emigration, death, or end of follow up, whichever
came first. In contrast, in the estimates of death by type
of subsequent breast event, follow up was started at the
diagnosis of that particular event. We calculated 95 %
CIs assuming a Poisson distribution for the observed
number of cases. All data preparation and analysis was
done using the SAS statistical package, version 8.2 or
higher (SAS Institute Inc., Cary, NC, USA). The regional
ethical committee in Stockholm approved the study.
Results
Patient characteristics are listed in Table 1. Over a follow-
up period of 71,458 person-years, 825 (10.2 %) women
developed 886 subsequent breast events (118 contralateral
in situ and 768 ipsilateral or contralateral invasive breast
cancers). The proportion of subsequent breast events was
similar in women with and without a family history
(11.3 %, n = 97 versus 10.0 %, n = 728). The average time
from the first in situ breast cancer diagnosis to a second
breast event was overall 5.6 years +/− 4.6 years.
Risk
Table 2 presents the risk of second invasive or in situ
breast cancer. The risk of a subsequent ipsilateral or
contralateral invasive breast cancer was increased more
than fourfold (SIR 4.6 (95 % CI 4.2–4.9)) among women
with in situ breast cancer as compared to women in the
general population. The risk of contralateral in situ breast
cancer was almost 16-fold increased (SIR 16.0 (95 % CI,
13.2–19.1)). Poisson regression analyses showed that
women with a family history of breast cancer had almost
50 % increased risk of contralateral invasive breast cancer,
compared to women without a family history of breast
cancer (adjusted IRR 1.5 (95 % CI 1.0–2.0)).
Among women diagnosed with in situ breast cancer,
the cumulative 10-year and 20-year risk of subsequent
contralateral or ipsilateral invasive cancer was approxi-
mately 10 % and 18 %, respectively, while the cumulative
10-year and 20-year risk of subsequent contralateral in
situ breast cancer was 1 % and 2 %, respectively (Fig. 1).
Table 1 Summary of all women diagnosed with in situ breast





Total 8111 7252 859
Mean age at first in situ breast
cancer (SD)
59.1 (12.1) 59.7 (12.1) 53.9 (10.8)
Mean follow-up time, years (SD) 8.8 (5.9) 8.3 (5.9) 7.7 (5.4)
Year at diagnosis of first in situ cancer
1980 − 1984 665 624 41
1985 − 1989 1211 1108 103
1990 − 1994 2046 1835 211
1995 − 1999 1963 1727 236
2000 − 2004 2226 1958 268
Age at diagnosis of first in situ cancer, years
< 40 335 269 66
40–44 594 507 87
45–49 1078 903 175
50–54 1313 1133 180
55–59 1133 993 140
60–64 1021 943 78
65–69 1058 995 63
70–74 778 748 30
75+ 801 761 40
Type of second events
Contralateral in situ 118 104 14
Ipsilateral invasive 376 334 42
Contralateral invasive 303 262 41
Total invasivea 768 677 91
Second breast event totala,b 886 781 105
Type of second events (women, n)
Contralateral in situa 117 103 14
Ipsilateral invasive 370 328 42
Contralateral invasive 299 258 41
Total invasivea 725 637 88
Second breast event totala,b 825 728 97
aIncludes the events where laterality is missing. 2bipsilateral in situ events were
not included in the study
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Women with in situ breast cancer and no family history
had increasing risk of subsequent invasive cancer during
the study period, with a SIR of 3.1 (95 % CI 2.4–3.9) in
1980–1984, vs. 5.0 (95 % CI 3.9–6.5) in 2000–2004 (P for
trend <0.001). In contrast, women with a family history
did not have increased risk of subsequent invasive breast
cancer over the study period (Table 3). The EAR also
increased over the study period for women with no family
history of breast cancer but did not increase in women
with a family history (Additional file 1: Table S1).
Overall, the relative risk of subsequent invasive breast
cancer was almost twice as high for women under 40 years
old at the first in situ breast cancer diagnosis compared
with women over 40 years, with SIRs of 8.5 (95 % CI
6.1–11.7) and 4.4 (95 % CI 4.1–4.8), respectively (P value
<0.001). Among women below 40 years, and who had a
positive family history, the risk of subsequent invasive
cancer was more than 14 times higher than in the general
population, with a SIR of 14.3 (95 % CI 7.4–25.0).
Given that the background rates of breast cancer are
highly age-dependent, we estimated the EAR in relation
to age at diagnosis. While the relative risk of a subse-
quent invasive breast event decreased with increasing
age, in both women with and without a family history of
breast cancer, the overall EAR was significantly increased
but was similar in women below 40 years of age at
diagnosis (93.2 per 10,000 person-years; 95 % CI
63.4–129.8) as compared to women over 40 (88.5 per
10,000 person-years; 95 % CI 80.4–97.0) (Additional file
1: Table S1). In contrast, women with a family history of
breast cancer had the highest EAR, with women under
40 years of age carrying the greatest EAR (154.1 per
10,000 person-years; 95 % CI 77.1–266.3), compared to
women older than 40 years at diagnosis (105.7 per
10,000 person-years; 95 % CI 78.9–136.8). This suggests
that both relative and absolute risks are higher with
younger age of onset of in situ disease in women with a
positive family history.
Finally, regardless of family history the risk of subse-
quent invasive cancer in the first 5 years after first in situ
breast cancer was increased more than fivefold compared
to the general population (SIR 5.2; 95 % CI 4.7–5.7). In
women with no family history there was a significant de-
cline in both the relative and absolute risk over time, but
this was not observed in women with a family history
(Table 3 and Additional file 1: Table S1).
Mortality
The overall risk of death in women with in situ cancer
was significantly increased by 30 % compared to the
general population but was highly dependent on the
occurrence of a second invasive cancer event (Table 4).
Table 2 Standardized incidence ratio (SIR) of a second breast event (contralateral in situ or ipsilateral or contralateral invasive breast
cancer) after diagnosis of first in situ breast cancer and its 95 % CI, by type of second breast event and family history
All No family history Family history Incidence rate ratiod
Number SIR Number SIR Number SIR
(95 % CI) (95 % CI) (95 % CI) (95 % CI)
Second breast cancera 886 5.1 (4.8–5.4) 781 5.0 (4.6 − 5.3) 105 6.3 (5.1–7.6) 1.2 (1.0–1.4)
Second contralateral in situa 118 16.0 (13.2–19.1) 104 15.8 (12.9–19.2) 14 17.4 (9.5– 29.3) 1.1 (0.6–1.9)
Second invasiveb 768 4.6 (4.2–4.9) 677 4.4 (4.1–4.7) 91 5.6 (4.5–6.9) 1.2 (1.0–1.5)
Second ipsilateral invasivec 376 4.3 (3.8–4.7) 334 4.2 (3.8–4.7) 42 5.0 (3.6–6.7) 1.00 (0.7– 1.4)
Second contralateral invasivec 303 3.4 (3.1–3.8) 262 3.3 (2.9–3.7) 41 4.8 (3.5–6.5) 1.5 (1.0–2.0)
aBackground rate of in situ breast cancer was divided by 2. bIincludes ipsilateral, contralateral and missing side. cBackground rate of invasive breast cancer was
divided by 2. dReference group is No family history. Incidence rate ratio has been adjusted for age and year of first diagnosis of in situ cancer and time since
first diagnosis
Fig. 1 Cumulative incidence of a second breast event among women diagnosed with in situ breast cancer, stratified by types of subsequent
breast events
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Table 3 Standardized incidence ratio (SIR) of second invasive breast cancer (ipsilateral and contra lateral) after diagnosis of first in
situ breast cancer, by year at first diagnosis, age at first diagnosis, time since first diagnosis and family history (years)
All No family history Family history
Number SIR 95 % CI Number SIR 95 % CI Number SIR 95 % CI
Calendar yeara
1980–1984 81 3.3 2.6–4.1 72 3.1 2.4 − 3.9 9 6.6 3.0–12.5
1985–1989 141 3.5 3.0 − 4.2 123 3.4 2.8–4.0 18 5.3 3.2–8.4
1990–1994 292 5.2 4.6 − 5.9 259 5.1 4.5–5.8 33 5.9 4.1–8.3
1995–1999 182 5.2 4.5 − 6.1 160 5.2 4.4–6.0 22 5.2 3.3–7.9
2000–2004 72 5.1 4.0 − 6.4 63 5.1 3.9–6.5 9 5.5 2.5–10.4
P value <0.001 <0.001 1
Age at diagnosis (years)
< 40 39 8.5 6.0–11.7 27 7.2 4.8–10.5 12 14.3 7.4–25.0
40–49 173 4.9 4.2–5.7 147 4.8 4.1–5.71 26 4.7 3.1–6.8
50–59 221 4.1 3.6–4.6 189 3.9 3.4–4.5 32 5.2 3.6–7.4
60–69 220 4.6 4.0–5.2 207 4.5 (4.0–5.2) 13 5.2 2.8–8.8
≥ 70 115 4.3 3.6–5.2 107 4.2 (3.4–5.1) 8 6.9 3.0–13.6
P trend 0.008 0.069 0.096
< 40 39 8.5 6.1–11.7 27 7.2 4.8–10.5 12 14.3 7.4–25.0
> 40 729 4.4 4.1–4.8 650 4.3 4.0–4.7 79 5.2 4.1–6.4
P value <0.001 0.012 0.001
Time since diagnosis (years)
0–4 401 5.2 4.7–5.7 359 5.1 4.6–5.7 42 5.5 3.9–7.3
5–9 230 4.4 3.9–5.1 197 4.2 3.6–4.8 33 6.5 4.5–9.2
10–14 96 3.4 2.8–4.2 85 3.3 2.6–4.1 11 4.3 2.1–7.7
> 15 41 3.4 2.4–4.6 36 3.2 2.2–4.4 5 5.9 1.9–13.8
P trend <0.001 <0.001 0.848
aOn restriction of the follow-up time to 5 years the estimates were similar but the trend tests not significant
Table 4 Standardized mortality ratio (SMR) with second breast events (contralateral in situ or ipsilateral or contralateral invasive
breast cancer) after diagnosis of first in situ breast cancer and its 95 % CI, by type of second breast event and family history
All No family history Family history <50 >50
Deaths (n) SMR Deaths (n) SMR Deaths (n) SMR Deaths (n) SMR Deaths (n) SMR
(95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI)
Overall 1343 1.28 1258 1.2 85 1.44 122 2.19 1221 1.24
(1.2–1.2) (1.2–1.4) (1.2–1.8) (1.8–2.6) (1.2–1.3)
No event + 2nd contralateral in situ 927 1.01 875 1.0 52 1.02 58 1.17 869 1.00
(1.0–1.1) (0.9–1.1) (0.8–1.3) (0.8–1.5) (0.9–1.1)
Second invasivea 132 2.06 122 2.03 10 2.54 29 8.03 103 1.7
(1.7–2.4) (1.7–2.4) (1.2–4.7) (5.4–11.5) (1.4–2.1)
Second ipsilateral invasive 63 2.16 58 2.12 5b 2.75 17 12.89 46 1.65
(1.7–2.8) (1.6–2.7) (0.9–6.4) (7.5–20.6) (1.2–2.2)
Second contralateral invasive 55 1.99 49 1.92 6b 2.82 10 7.85 45 1.71
(1.5–2.6) (1.4–2.5) (1.0–6.2) (3.8–14.4) (1.2–2.3)
aIncludes ipsilateral, contralateral and missing side. bOne subject had both ipsilateral and contralateral invasive breast cancer, which is why the total
is 6 + 5 = 11 > 10
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Women who did not have a second invasive event
following in situ breast cancer, had a similar risk of
death to women in the background population (SMR 1.0
(95 % CI 1.0–1.1)). In contrast, women who were diag-
nosed with an invasive breast cancer event after in situ
breast cancer were twice as likely to die as compared to
women in the general population (SMR 2.1 (95 % CI
1.7–2.4)), with no significant differences between women
with and without a family history of breast cancer.
The overall risk of death following in situ breast
cancer was increased in women with a family history
(SMR1.4 (95 % CI 1.2–1.8)) and in women without
family history (SMR 1.3 (95 % CI 1.2–1.4)). Given that
deaths were rare at younger ages, we compared mortal-
ity among women above and below age 50 years.
Women below age 50 years at the first in situ breast
cancer diagnosis and who were diagnosed with a second
invasive cancer, had significantly higher mortality as
compared to women over 50 years at diagnosis (SMR
8.0; 95 % CI 5.4–11.5 vs. SMR 1.7; 95 % CI 1.4–2.0). The
laterality of the second invasive event did not influence
the risk of death significantly.
Discussion
In this large population-based cohort, with data from
nationwide, high-quality registers, we demonstrate that
women diagnosed with in situ breast cancer have a con-
siderably increased risk of invasive breast cancer and
contralateral in situ breast cancer, compared to women
in the general population, with young women facing the
highest risk. Having a positive family history increases
the risk exclusively for a contralateral invasive breast
cancer by 50 % compared to not having a family history
of breast cancer. The increased risk of invasive cancer
persists over time, and at fifteen years after diagnosis the
risk is still three times higher than in women in the
general population. Meanwhile, the mortality for women
with in situ breast cancer is the same as the general
population, as long as invasive cancer does not occur.
In women with a positive family history, the risk of
contralateral invasive breast cancer was more than four
times as high as for women in the general population and
almost 50 % higher compared to women with no family
history of breast cancer. The observed increased risk is
approximately twice as high as the risk of breast cancer
that is faced by women without previous breast cancer,
who have a positive family history of breast cancer. There
are methodological issues that may account for these
differences, because our estimates assume only one breast
is at risk, with a corresponding lower expected rate.
Two meta-analyses of familial risks of breast cancer
report the relative risk associated with having a first-
degree relative with breast cancer as 2.1 and 1.8, respect-
ively [28, 29]. The observed diluted additional risk in
women with a family history, i.e., only 50 % increased
risk of a contralateral invasive cancer, and no increased
risk for ipsilateral invasive cancer or contralateral in situ
cancer, as compared to women with no family history, is
intriguing. We speculate that women with a positive
family history were likely more prone to choose mastec-
tomy than those without family history, which would
reduce the risk of an ipsilateral cancer in these women.
The reduced risk may also be a reflection of heterogen-
eity of the in situ breast cancer phenotype. Additional
stratification into one, two or even three affected first--
degree members to better quantify the hereditary com-
ponent may have allowed a deeper understanding of
these results.
Regardless of family history, women under 40 years of
age at diagnosis had a significantly higher risk of subse-
quent invasive breast cancer compared to women above
40 years. These young women would experience an
absolute excess risk ranging from about 8 events per
1000 person-years to as many as 15 events per 1,000
person-years depending on family history; this absolute
excess risk decreases with increasing age only in women
with a positive family history. Given that a younger
woman with both high risk of a subsequent event and a
longer life expectancy, which translates to higher cumu-
lative risk, mastectomy may be considered to a greater
extent in this patient population.
The increased relative risk of subsequent invasive breast
cancer by almost 60 % from the period 1980–1984 to the
period 2000–2004, exclusively in women with no family
history, may be related to a combination of screening and
treatment patterns. A nationwide mammography screen-
ing program was introduced during the study period,
which had complete national coverage by 1997 [30]. Thus,
the means of detection of in situ breast cancer changed
during the study period, from symptom-detected to
screening-detected, with better prognosis for the latter
[31]. However, in this study the risk of subsequent invasive
breast cancer increased during the study period and this
might reflect that with increasing mammography screen-
ing and subsequently a larger number of smaller lesions
detected, the use of breast-conserving surgery became the
norm from 1990 onwards [32]. In comparison to mastec-
tomy, breast-conserving surgery poses an increased risk of
both local recurrence and new ipsilateral primary cancer.
In contrast, women with a positive family history had no
increased risk during the study period and we speculate
that these women, who had relatives with breast cancer,
were more prone to choosing mastectomy.
Treatment for in situ breast cancer during the study
period was performed according to regional and national
guidelines [32]. Surgery involved either mastectomy or
breast-conserving surgery, and since the 1990s breast-
conserving surgery for in situ breast cancer has been
Sackey et al. Breast Cancer Research  (2016) 18:105 Page 6 of 9
recommended whenever feasible. Several randomized
trials, including the Swedish National DCIS study, have
unanimously shown a decreased rate of ipsilateral in situ
or invasive breast cancer recurrence through the addition
of adjuvant radiotherapy after breast-conserving surgery
[19, 33–37], and today, national guidelines include radio-
therapy up to a total of 50 Gray after breast-conserving
therapy in patients with ductal carcinoma in situ [32].
However, during most of the study period adjuvant radio-
therapy was not recommended for the majority of patients
who were treated with breast-conserving surgery, which
might reflect the increased relative risk of a second
invasive event in the latter parts of the study period when
breast-conserving surgery become more frequent.
During follow up, women with no family history of
breast cancer had a gradually decreasing risk of subse-
quent invasive breast cancer with time since diagnosis.
However, 15 years after the first in situ breast cancer, the
risk for an invasive breast cancer was still almost three
times higher than for women in the general population.
This indicates that women diagnosed with in situ breast
cancer have a lifelong increased risk, which needs to be
taken into account when planning their follow up.
Overall, there was no increased risk of death for women
with in situ breast cancer as long as there was no second
invasive event, but in women with a second invasive
breast cancer the risk of death was doubled. There were
no significant differences in mortality between women
with and without family history of breast cancer. Young
age of onset was an important predictor of death for
women with in situ disease due to an increased risk for
second invasive cancers and thus a substantially higher
mortality, which should be taken into account when
planning their treatment and follow-up.
In women with elevated risk of breast cancer, studies
have shown that adjuvant endocrine therapy with a select-
ive estrogen receptor modulator or an aromatase inhibitor
reduces the risk by 40–50 % [38–40], and in women with
lobular and ductal cancer in situ some studies suggest that
the benefits are even greater [12, 38, 41, 42]. Today,
national Swedish guidelines do not support the use of
adjuvant endocrine therapy after standard therapy for
ductal cancer in situ, and for lobular cancer in situ surgi-
cal or adjuvant treatment is still not recommended. One
must weigh the benefits of endocrine therapy in reducing
second breast cancer events against an increased risk of
side effects. In a systematic review and meta-analysis the
number needed to treat in order for Tamoxifen to have a
protective effect against all breast events was 15 and it did
not reduce the risk of all-cause mortality [43].
Strengths of the current study include the population-
based design, the large sample size, complete follow up
and unbiased ascertainment of family history, cancers
and death. To the best of our knowledge, this is the
largest study to assess the impact of a positive family
history of breast cancer on risk and mortality after in
situ breast cancer.
This study has a number of limitations. We have no
information on the mode of detection, tumor grade or
adjuvant treatment, and have not distinguished between
mastectomies and breast-conserving surgery, or ductal
carcinoma in situ and lobular carcinoma in situ. With
this stated, a previous Swedish case–control study has
shown that the risk of a subsequent invasive breast
cancer was equal after lobular and ductal carcinoma in
situ breast cancer [17]. One study has shown that for
women with lobular carcinoma in situ, family history
does not increase the risk of invasive breast cancer [12],
thus among women with ductal carcinoma in situ and a
positive family history, the risk estimates might be
higher than shown in our study. During the study
period, Sweden did not have a nationwide register on
local recurrences and in the vast majority of regions, a
second ipsilateral in situ breast cancer event was not
reported. Therefore, new ipsilateral in situ cancer was
not included in the study, as these events most probably
would be underestimated.
Conclusions
Among women with in situ breast cancer, a positive
family history of breast cancer increases the risk of
contralateral invasive breast cancer by almost 50 %. The
risk of subsequent invasive breast cancer and of mortal-
ity is substantially higher in younger women, which
should be taken into account when planning their treat-
ment and follow up.
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